… Epidermal growth factor receptor (EGFR) –tyrosine kinase inhibitors have proven efficacy
in advanced non–small-cell lung cancer (NSCLC). We hypothesized that erlotinib would be …

… in non–small cell lung cancer (NSCLC), and patient prognosis is poor. Erlotinib, a specific
inhibitor of … This study evaluates erlotinib in the treatment for brain metastases from NSCLC. …

… Patients who crossed over to erlotinib had a median survival of 14.9 months. Sex, histology,
… outcome with erlotinib. Rash and diarrhea were more common with erlotinib; emesis, …

… Erlotinib is an epidermal growth factor receptor (EGFR) … -cell lung cancer (NSCLC). Skin
rash and diarrhea are well-known and common adverse events in patients receiving erlotinib, …

… Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer
harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, …

… First-line gefitinib for patients with advanced non–small-cell lung cancer harboring … First-line
gefitinib for patients with advanced non–small-cell lung cancer harboring epidermal growth …

… A phase III trial was conducted to compare the safety and efficacy of erlotinib with that of
gefitinib in advanced non-small cell lung cancer harbouring epidermal growth factor receptor …

… Patients were stratified by EGFR mutation type, ECOG PS, gender, and country. … , erlotinib
patients could crossover to receive GP and GP patients could crossover to receive erlotinib. All …

… with advanced non-small-cell lung cancer (… lung cancer tumorigenesis. We compared the
efficacy of cabozantinib alone or in combination with erlotinib versus erlotinib alone in patients …

… tumor growth and progression in many cancers1, 2 and EGFR overexpression occurs in up
to 80% of non-small cell lung cancers (NSCLC).3, 4 Erlotinib … patients with relapsed NSCLC. …